What is CJC-1295 No DAC (5mg) / Ipamorelin (5mg)?

CJC-1295 No DAC (5 mg) / Ipamorelin (5 mg) is a dual-peptide research formulation categorized under Muscle Growth & Performance Peptides. It combines two synthetic peptides commonly used in laboratory research to study growth hormone–related signaling and endocrine communication under controlled experimental conditions.

CJC-1295 No DAC, also known as Modified GRF (1-29), is a short-acting peptide fragment derived from growth hormone–releasing hormone (GHRH). Ipamorelin is a selective growth hormone secretagogue peptide studied for its interaction with ghrelin-associated signaling pathways. When used together in research settings, the combination allows investigators to examine complementary peptide signaling mechanisms without the prolonged binding effects associated with DAC-modified peptides.

This formulation is intended strictly for laboratory research use and is supplied in a standardized, lyophilized format to support reproducibility and consistency across experimental workflows.

Product Specifications

• CAS Numbers:

  • CJC-1295 No DAC: 863288-34-0

  • Ipamorelin: 170851-70-4

• Peptide Sequences:

  • CJC-1295 No DAC (MOD-GRF 1-29):

    
    

    Tyr–D-Ala–Asp–Ala–Ile–Phe–Thr–Gln–Ser–Tyr–Arg–Lys–Val–Leu–Ala–Gln–Leu–Ser–Ala–Arg–Lys–Leu–Leu–Gln–Asp–Ile–Leu–Ser–Arg

  • Ipamorelin:

    
    

    Aib–His–D-2-Nal–D-Phe–Lys–NH₂

• Purity: Typically ≥95% (verified by HPLC and mass spectrometry)

• Packaging Format: Lyophilized powder, combined total of 10 mg per vial (5 mg each peptide)

• Storage Conditions: Store at −20 °C; protect from light and moisture

Key Characteristics of CJC-1295 No DAC (5mg) / Ipamorelin (5mg)

• Dual-peptide formulation designed for controlled laboratory research

• Synthetic peptides manufactured for batch consistency and reproducibility

• Lyophilized presentation supports stability during storage and handling

• Frequently used in endocrine and metabolic signaling research models

• Verified using standard analytical methods such as HPLC and MS

• Compatible with standard peptide handling and storage protocols

How CJC-1295 No DAC (5mg) / Ipamorelin (5mg) Supports Research

In laboratory studies, CJC-1295 No DAC and Ipamorelin are used to explore growth hormone–related signaling through distinct but complementary pathways. CJC-1295 No DAC is studied for its interaction with GHRH-associated mechanisms, while Ipamorelin is examined for its selective engagement with ghrelin-related receptors. Together, they allow researchers to investigate coordinated peptide signaling responses in endocrine and metabolic research models.

Research Applications & Usage Information

CJC-1295 No DAC (5 mg) / Ipamorelin (5 mg) is commonly used in laboratory research involving:

• Growth hormone signaling and pituitary-related pathways

• Endocrine communication and peptide interaction studies

• Metabolic regulation and energy-balance research models

• Cellular signaling and protein interaction studies

• Comparative peptide research evaluating short-acting signaling dynamics

All applications are limited to controlled in vitro or preclinical research environments.

Handling and Storage Recommendations

• Store unreconstituted vials at −20 °C in a dry, light-protected environment

• Allow vials to equilibrate to room temperature before opening to prevent moisture condensation

• After reconstitution, store solutions at 2–8 °C and use within laboratory-defined timeframes

• Avoid repeated freeze–thaw cycles to preserve peptide integrity

Compliance and Legal Considerations

Research Use Only Notice

This product is intended for laboratory research use only and is not approved for human or veterinary use. It is not intended for diagnostic, therapeutic, or clinical applications. Any reference to biological activity or potential effects is based solely on preclinical or in vitro findings and should not be interpreted as validated clinical outcomes. Researchers are responsible for ensuring proper handling, storage, and disposal in accordance with institutional, federal, and international guidelines.

References

Alba M, Fintini D, Sagazio A, et al. Once-daily administration of CJC-1295, a long-acting growth hormone-releasing hormone (GHRH) analog, normalizes growth in the GHRH knockout mouse. Am J Physiol Endocrinol Metab. 2006;291(6):E1290-E1294. doi:10.1152/ajpendo.00201.2006

Alba M, Schally AV, Salvatori R. Partial reversibility of growth hormone (GH) deficiency in the GH-releasing hormone (GHRH) knockout mouse by postnatal treatment with a GHRH analog. Endocrinology. 2005;146(3):1506-1513. doi:10.1210/en.2004-1044

Sagazio A, Xiao X, Wang Z, Martari M, Salvatori R. A single injection of double-stranded adeno-associated viral vector expressing GH normalizes growth in GH-deficient mice. J Endocrinol. 2008;196(1):79-88. doi:10.1677/JOE-07-0312